Self-Assembling Peptide Hydrogel for Glucose-Responsive Insulin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glucose-responsive insulin delivery systems face limitations such as protein denaturation under physiological conditions, cytotoxicity issues, and challenges in functioning at or near physiological pH, which restrict their implantable applications and effectiveness in maintaining normoglycemia in diabetic patients.
Innovation Solution
A phenylboronic acid (PBA) based glucose-sensitive insulin delivery system using self-assembling amphiphilic peptides that form a hydrogel, encapsulating insulin, which changes conformation and releases insulin in response to glucose levels at physiological pH, thereby controlling blood glucose levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucose oxidase based enzymatic reaction systems are used for glucose-responsive insulin delivery, then glucose responsiveness is achieved, but protein denaturation occurs under physiological conditions
Solution Approach 1:
The patent extracts the glucose sensing function from protein-based systems and implements it using phenylboronic acid moieties that bind glucose through reversible non-covalent interactions. This removes the denaturation problem while maintaining glucose responsiveness, as the boronic acid-glucose binding is based on chemical affinity rather than protein folding.
Solution Approach 2:
The patent replaces the enzymatic mechanism (glucose oxidase) with a chemical binding mechanism (phenylboronic acid-glucose complex formation). This substitution eliminates the biological protein stability issues while achieving the same glucose-responsive function through a more stable chemical interaction system.
2Reliability
If lectin binding protein Concanavalin A based systems are used, then glucose binding capability is achieved, but cytotoxicity issues arise
Solution Approach 1:
The patent uses phenylboronic acid moieties that can be easily attached to polymer chains and provide transient, reversible glucose binding. These small molecular units are non-toxic and can be discarded or degraded without causing harm, unlike the large protein-based Concanavalin A systems that cause cytotoxicity.
Solution Approach 2:
The patent changes the molecular size and chemical nature of the glucose-binding unit from large proteins (Concanavalin A) to small phenylboronic acid moieties. This parameter change reduces the molecular weight and eliminates cytotoxic effects while maintaining glucose binding capability through chemical affinity.
3Reliability
If phenylboronic acid based systems are used, then glucose binding at physiological pH is achieved, but device complexity increases
Solution Approach 1:
The patent merges the glucose sensing function and insulin delivery function into a single integrated hydrogel system. The phenylboronic acid moieties are incorporated directly into the hydrogel matrix, allowing simultaneous glucose binding and insulin release without requiring separate sensors or delivery mechanisms, thus reducing overall system complexity.
Solution Approach 2:
The phenylboronic acid-based hydrogel system performs multiple functions: glucose sensing, glucose binding, and insulin delivery through a single material platform. This multi-functionality reduces device complexity by eliminating the need for separate components required in other systems.
4Reliability
If self-assembling amphiphilic peptides are used to form hydrogel, then insulin encapsulation and glucose-responsive release are achieved, but manufacturing precision requirements increase
Solution Approach 1:
The patent performs preliminary self-assembly of the amphiphilic peptides into hydrogel structures before insulin encapsulation. This pre-formed hydrogel matrix provides a stable framework that simplifies subsequent insulin loading and ensures consistent release behavior, reducing the need for high precision during manufacturing.
Solution Approach 2:
The patent optimizes the peptide sequence and hydrophobicity parameters to control self-assembly behavior. By adjusting these parameters, the hydrogel forms under mild conditions with consistent morphology, reducing manufacturing precision requirements while maintaining reliable insulin encapsulation and release control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system effectively maintains blood glucose levels within a safe range by releasing insulin in response to changing glucose concentrations, avoiding both hyper- and hypoglycemia, and can be administered subcutaneously, intradermally, or intramuscularly, providing a 'smart' release mechanism for glucose regulation.
Implementation Method 1
which changes conformation and releases insulin in response to glucose levels at physiological pH
Implementation Method 2
using self-assembling amphiphilic peptides that form a hydrogel
Implementation Method 3
A phenylboronic acid (PBA) based glucose-sensitive insulin delivery system
Data Source
AI summary
A glucose binding amphiphilic peptide hydrogel insulin delivery system that is responsive to glucose concentrations under physiological conditions is provided. Insulin is encapsulated in a glucose binding hydrogel, made from self-assembling amphiphilic peptides including a hydrophobic domain including a beta sheet forming region coupled to a charged hydrophilic domain modified to contain a glucose binding segment. The formulations are designed to release insulin as a function of blood glucose level, maintaining the patients' blood glucose level in an optimum range and avoiding both hyper- and hypoglycemia.